Third-Generation EGFR-TKIs in T790M-Negative NSCLC After First/Second-Generation EGFR-TKI Failure: A Retrospective...

Area of Science:

• Oncology
• Pharmacology
• Medical Genetics

Background:

• Non-small cell lung cancer (NSCLC) treatment resistance to first- and second-generation EGFR-TKIs poses a clinical challenge.
• Only a subset of resistant NSCLC patients develop the T790M mutation, limiting eligibility for third-generation EGFR-TKIs.
• Chemotherapy is the standard second-line treatment for T790M-negative NSCLC patients.

Purpose of the Study:

• To compare the efficacy of third-generation EGFR-TKIs versus chemotherapy in T790M-negative advanced NSCLC patients.
• To evaluate treatment outcomes for patients resistant to first- or second-generation EGFR-TKIs but lacking the T790M mutation.

Main Methods:

• Retrospective analysis of 82 T790M-negative advanced NSCLC patients progressing after first- or second-generation EGFR-TKIs.
• Patients received either third-generation EGFR-TKIs (n=45) or chemotherapy and/or earlier-generation EGFR-TKIs (n=37).
• Collected data included clinical characteristics, disease features, and survival outcomes.

Main Results:

• Third-generation EGFR-TKIs demonstrated significantly longer median progression-free survival (mPFS) at 10.20 months compared to other treatments (5.70 months, p=0.017).
• Subgroup analysis showed third-generation EGFR-TKIs were superior to first/second-generation EGFR-TKIs with or without chemotherapy (p<0.001 and p=0.004).
• Median overall survival (mOS) was 39.80 months for third-generation EGFR-TKIs versus 32.40 months for non-third-generation therapy (p=0.408).

Conclusions:

• Third-generation EGFR-TKIs significantly improve mPFS in T790M-negative advanced NSCLC patients resistant to prior EGFR-TKIs.
• This finding supports the use of third-generation EGFR-TKIs as a viable and effective treatment option for this specific patient population.
• Further research may explore optimal sequencing and combination strategies.